RIO-LIPIDS研究
Rimonabant in Obesity
Presented at
American College of Cardiology
Scientific Sessions 2004
Presented by Dr. Jean-Pierre Despres
RIO LIPIDS Trial
Rimonabant
A selective cannabinoid type 1 receptor antagonist
5 mg
n=345
Endpoints (1 year):
Weight loss ?5% of body weight and ?10% of body weight
Change in lipid profile
RIO LIPIDS Trial
Presented at ACC Scientific Sessions 2004
1,036 patients with abdominal obesity and
abnormal lipid profiles
Randomized, double-blind, multicenter
Placebo
n=342
Rimonabant
A selective cannabinoid type 1 receptor antagonist
20 mg
n=346
Treatment for 1 Year
RIO LIPIDS Trial
Weight Loss ?5%
p < 0.001 for high-dose vs placebo
Presented at ACC Scientific Sessions 2004
Weight Loss ?10%
p < 0.001 for high-dose vs placebo
RIO LIPIDS Trial
Relative Reduction in CRP
p=0.007 for rimonabant 20 mg vs placebo
C-reactive protein reduction greater in rimonabant 20 mg arm compared with placebo (from 3.7 to 2.7 mg/l with rimonabant 20 mg vs. 3.6 to 3.2 mg/l with placebo, p=0.007)
HDL increased 23% and triglycerides decreased 15% in rimonabant 20 mg, but no significant difference in LDL levels
Presented at ACC Scientific Sessions 2004
RIO LIPIDS Trial
Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo
Additional benefits were observed in HDL and triglyceride levels with rimonabant
Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia
Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study
Further evaluation is warranted